Curie.Bio Raises $380M to Support Early-Stage Biotechs

1. Funding: Curie.Bio, a biotech accelerator and venture capital firm, has raised $380 million to support its portfolio companies beyond the seed stage.
2. Purpose: The funds will primarily be used to support Series A rounds for nascent startups that graduate from Curie.Bio's accelerator program.
3. Founders: Curie.Bio was co-founded by Alexis Borisy and Zach Weinberg, with Christoph Lengauer serving as the chief scientific officer.
4. Services: The company offers a range of services, including "Curie co-pilots," which provide drug hunters and biotech leaders to help develop a seed work plan, budget planning, vendor selection, expert recruiting, and a roadmap to critical scientific milestones.
5. Investments: Curie.Bio has invested in 20 companies with programs offering "blockbuster potential," spanning across the U.S., Canada, Europe, and Australia, and covering a wide range of modalities and therapeutic areas.
6. Previous Funding: This latest haul follows a $520 million initial fund, bringing Curie.Bio's total to nearly $1 billion.
7. Location: Curie.Bio is based in Cambridge, Massachusetts.